Scottish Government pledges 800 more GPs over the next ten years

Scottish Government pledges 800 more GPs over the next ten years

December 5 2017 The Scottish Government has announced it will aim to increase the number of GPs...

‘Highest ever number of people entering GP training in NHS history’ recorded

‘Highest ever number of people entering GP training in NHS history’ recorded

November 30 2017 The number of people entering GP training increased by 138 to 3,157, new data...

PHW issues advice regarding ordering flu vaccination stock for the 2018-19 season

PHW issues advice regarding ordering flu vaccination stock for the 2018-19 season

November 29 2017 Public Health Wales has written to GPs with advice regarding stock ordering...

Practices asked to address communication needs of people with sensory loss

Practices asked to address communication needs of people with sensory loss

November 27 2017 General practices are being asked to ensure information they provide is made...

Wales exceeds GP training places target

Wales exceeds GP training places target

November 21 2017 Recruitment into GP training places in Wales has passed the target set for this...

  • Scottish Government pledges 800 more GPs over the next ten years

    Scottish Government pledges 800 more GPs over the next ten years

    Tuesday, 05 December 2017 11:08
  • ‘Highest ever number of people entering GP training in NHS history’ recorded

    ‘Highest ever number of people entering GP training in NHS history’ recorded

    Thursday, 30 November 2017 09:30
  • PHW issues advice regarding ordering flu vaccination stock for the 2018-19 season

    PHW issues advice regarding ordering flu vaccination stock for the 2018-19 season

    Wednesday, 29 November 2017 12:53
  • Practices asked to address communication needs of people with sensory loss

    Practices asked to address communication needs of people with sensory loss

    Monday, 27 November 2017 14:57
  • Wales exceeds GP training places target

    Wales exceeds GP training places target

    Tuesday, 21 November 2017 15:01

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Management News

December 13 2017 Women using hormonal contraceptives are exposed to a 20% increased risk of developing breast cancer, a 17-year-long study has shown. The relative risk is considered small, however,...
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...